Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

KineMed, Roche to validate KineMarker technology
April 2007
SHARING OPTIONS:

EMERYVILLE, Calif.—Early March saw KineMed Inc., a pathway-based drug discovery and development company, enter into a collaboration with Roche to jointly validate KineMed's novel translational KineMarker technology. KineMed's technology measures the on-mechanism activity of compounds in whole body systems in animals and man, accelerating the translation of promising therapeutic agents into advanced clinical studies.
 
In collaboration with Roche, KineMed will clinically validate its proprietary KineMarker of collagen synthesis, a dynamic therapeutic target underlying tissue fibrosis, in an undisclosed disease area.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.